

# Rheumocam 2.5mg Chewable Tablets for Dogs

## **Composition:**

Meloxicam 2.5 mg

## **Product Description:**

Off white to pale yellow coloured, flat surface beveled edged tablets with a breakline on one side.

## **Pharmacodynamics:**

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

## **Pharmacokinetics:**

### Absorption

Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 4.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.

### Distribution

There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg.

### Metabolism

Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

### Elimination

Meloxicam is eliminated with a half-life of 24 hours. Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.

## **Indication:**

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.

**Routes of administration:** Oral

**Dosage:**

Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day.

Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.

Each chewable tablet contains 2.5 mg meloxicam, which corresponds to the daily maintenance dose for a 25 kg body weight dog respectively. Each chewable tablet can be halved for accurate dosing according to the individual body weight of the animal. Rheumocam chewable tablets can be administered with or without food, are flavoured and are taken by most dogs voluntarily.

Dose scheme for the maintenance dose:

Body weight (kg)	Number of chewable tablets	mg/kg
20.1- 25.0	1	0.12 – 0.1
25.1- 35.0	1½	0.15 – 0.1
35.1- 50.0	2	0.14 – 0.1

The use of Rheumocam oral suspension for dogs may be considered for an even more precise dosing. For dogs weighing less than 4 kg the use of Rheumocam oral suspension for dogs is recommended.

A clinical response is normally seen within 3–4 days. Treatment should be discontinued after 10 days if no clinical improvement is apparent.

**Contraindications:**

Do not use in pregnant or lactating animals.

Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in dogs less than 6 weeks of age or less than 4 kg body weight.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

**Warnings and Precautions:****Special warnings for each target species**

None.

**Special precautions for use in animals**

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.

**Special precautions to be taken by the person administering the veterinary medicinal product to animals**

People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In the case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

**Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

**Interactions with other medicaments:**

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Rheumocam must not be administered in conjunction with other NSAIDs or glucocorticosteroids.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such medicines should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.

**Statement on usage during pregnancy and lactation:**

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

**Adverse Effects:**

Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported. In very rare cases haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported. These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

**Overdose:**

In case of overdosage symptomatic treatment should be initiated.

**Storage Conditions:**

Do not store above 25°C.

**Packing:** 100 tablets

FOR VETERINARY USE ONLY

**Manufactured by:**

**Chanelle Pharmaceuticals Manufacturing Ltd.,**  
Loughrea, Co. Galway, Ireland.

**Registration holder and repacker:**



**Rhone Ma Malaysia Sdn Bhd (525887-w)**

Lot 18A & 18B, Jalan 241, Seksyen 51A,  
46100 Petaling Jaya, Selangor, Malaysia  
Tel: 03-7873 7355 Fax: 03-7873 9209  
E-mail: customercareline@rhonema.com

**Date of revision of package insert:** Mar 2018

<b>LABEL CODE:</b>	<b>VERSION</b>	<b>COLORS</b>
PRODUCT: RHEUMOCAM 2.5MG CHEWABLE TABLETS FOR DOGS  PACK SIZE: 100 tablets  COUNTRY: MY  DIMENSIONS: cm =	Version: 1  MMM/YY:	

<b>Marketing approval:</b>	<b>Regulatory approval:</b>
COMPLETE NAME:	COMPLETE NAME:
DATE:	DATE:
SIGNATURE:	SIGNATURE: